Aquagenic Pruritus in Myeloproliferative Neoplasms

Completed

• Conditions: Deciphering Aquagenic Pruritus in Myeloproliferaitive Neoplasms

• Registration Number: NCT04018209
• Lead Sponsor: University Hospital, Brest

Brief Summary

Description of the characteristics of aquagenic pruritus expressed by patients suffering from myeloproliferative neoplasms.

Prospective work based on the distribution of a dedicated questionnaire.

Detailed Description

Patients with myeloproliferative neoplasms identified and followed in French Hospitals. Patients could be followed for polycythemia vera or essential thrombocythemia or primary myelofibrosis.

Distribution of the questionnaire to each patient with myeloproliferative neoplasm (treated or not) suffering from aquagenic pruritus.

Analyse of each characteristic of the aquagenic pruritus by a statistician and publication at the end.

Study Timeline

• Study First Submitted: 2019-05-24
• Study Start: 2019-07-09
• Study First Submitted QC: 2019-07-10
• Study First Posted: 2019-07-12
• Primary Completion: 2020-01-09
• Study Completion: 2021-01-06
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-30
• Last Update Posted: 2024-11-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 170

Inclusion Criteria

• Patients with one of three non-chromosomal Philadelphia-positive myeloproliferative neoplasms: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
• Suffering (or having suffered) from aquagenic pruritus.
• No age limit, but major
• Patient having formulated his non-opposition

Exclusion Criteria

• Patients with MPN with non-aquagenic pruritus,
• Patients with another hematologic disease and aquagenic pruritus
• Patients unable to complete the questionnaire.
• Patients with physical or mental disabilities to formulate non-opposition
• Refusal of participation

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Description of pruritus in patients with myeloproliferative neoplasms	at the time of questionnaire completion (Day 0)	Intensity of pruritus (visual analogic scale)

Secondary Outcome Measures

Name	Time	Method
Description of therapies used to treat pruritus	at the time of questionnaire completion (Day 0)	Name of drugs used

Trial Locations

Locations (11)

05; 🇫🇷 Lyon, Auvergne Rhônes-alpes, France

10; 🇫🇷 Quimper, Brestagne, France

11; 🇫🇷 Morlaix, Bretagne, France

09; 🇫🇷 Saint-Brieuc, Bretagne, France

07; 🇫🇷 Saint-Louis, Grand Est, France

03; 🇫🇷 Annecy, Haute-Savoie, France

04; 🇫🇷 Roubaix, Hauts-de-France, France

08; 🇫🇷 Rochefort, Nouvelle Aquitaine, France

06; 🇫🇷 Angers, Pays de la Loire, France

02; 🇫🇷 Villejuif, Val-de-marne, France

01; 🇫🇷 Brest, France